Longitudinal neuropsychological findings from Stony Brook first episode study

Hoff, Anne L.; Wieneke, Mary; Horon, Robert; Sakuma, Michael; Nordahl, Thomas E.; DeLisi, Lynn E.

doi:10.1016/s0920-9964(97)82299-2

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of full-scale IQ, which the authors used as a measure of general cognitive function, the decrease in negative symptoms explained the 8% variance of its improvement. Fluctuations in cognitive performance secondary to both positive [25] and negative [12,20] symptom changes have also been reported in other longitudinal studies. In short, psychotic symptoms, although not the cause of cognitive impairment, play a moderate modulating role in cognitive performance.…”

Section: Discussionsupporting

confidence: 60%

Neuropsychological functioning in adolescents with first episode psychosis: A two-year follow-up study

et al. 2008

View full text Add to dashboard Cite

Cognitive deficits are a core feature of psychotic disorders. Both in adult and adolescent populations, studies have shown that patients with psychosis have poorer cognitive functioning than controls. The cognitive domains that seem to be affected are mainly attention, working memory, learning and memory, and executive function. However, with regard to the trajectory of cognitive function throughout the illness, there is still a dearth of prospective data in patients who develop psychosis during adolescence. In this article, neuropsychological functioning was assessed in a sample of 24 first episodes of early onset psychosis (EOP) and 29 healthy adolescents at baseline and after a two-year follow-up. Patients with EOP showed lower scores than controls in overall cognitive functioning and in all specific domains assessed (attention, working memory, executive function, and learning and memory) both at baseline and the two-year follow-up. When changes in cognitive functioning over two years were assessed, patients and controls showed significant improvement in almost all cognitive domains. However, this improvement disappeared in the patient group after controlling for improvement in symptomatology. Our findings support a neurodevelopmental pathological process in this sample of adolescents with psychosis.

show abstract

Section: Discussionsupporting

confidence: 60%

Neuropsychological functioning in adolescents with first episode psychosis: A two-year follow-up study

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The difference between these latter assessment dates was significant ( t = 4.0, df = 49, p < 0.01). Owing to the stability of neurocognitive functions in first episode of psychosis [3,24,26] and the relative small difference between the neurocognition–SUMD/PANSS interval compared to the neurocognition–BCIS interval (about 18 days) it is unlikely that this difference was of much significance. Moreover, virtually all patients were tested at least 3 months after admission to PEPP and were relatively stable at the time of insight evaluation.…”

Section: Methodsmentioning

confidence: 99%

Cognitive insight and verbal memory in first episode of psychosis

Lepage¹,

Buchy²,

Bodnar³

et al. 2008

Eur. psychiatr.

View full text Add to dashboard Cite

Beck and collaborators have proposed a distinction between clinical insight and cognitive insight and have developed a tool for the assessment of the latter, namely the Beck Cognitive Insight Scale (BCIS). The present study explored in 51 patients with a first episode of psychosis the neurocognitive correlates of cognitive insight as assessed with the BCIS. Global measures for seven domains of cognition including verbal learning and memory, visual learning and memory, working memory, speed of processing, reasoning and problem solving, attention, and social cognition were examined. Secondly, we examined whether two clinical insight measures, the Scale to assess Unawareness of Mental Disorder (SUMD) and the insight item from the Positive and Negative Symptoms Scale (PANSS), could produce similar or different patterns of association with neurocognitive functions as those identified with the BCIS. Correlational analyses revealed significant associations between the BCIS Composite Index and the verbal learning and memory. No significant associations were observed between any of the neurocognitive domains and the PANSS or SUMD clinical insight measures, despite high inter-correlations among the three insight measures. These results suggest that cognitive insight, but not clinical insight, may rely on memory processes whereby current experiences are appraised based on previous ones.

show abstract

“…The severity of cognitive symptoms is a better indicator of social and functional outcome than the severity of negative or positive symptoms [14,16,19,24–26,41,39]. Patients who have the most severe cognitive deficits during the first episode of the disease are most likely to later present a chronic and severe form of schizophrenia [6,30,43]. The relationship between cognitive deficits and functional prognosis seems stable [1,10,36] as shown in cross-sectional and longitudinal studies alike [16].…”

Section: Introductionmentioning

confidence: 99%

Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients

et al. 2007

View full text Add to dashboard Cite

Schizophrenic patients demonstrate impairments in several key dimensions of cognition. These impairments are correlated with important aspects of functional outcome. While assessment of these cognition disorders is increasingly becoming a part of clinical and research practice in schizophrenia, there is no standard and easily administered test battery. The BACS (Brief Assessment of Cognition in Schizophrenia) has been validated in English language [Keefe RSE, Golberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensibility, and comparison with a standard neurocognitive battery. Schizophr. Res 2004;68:283-97], and was found to be as sensitive to cognitive dysfunction as a standard battery of tests, with the advantage of requiring less than 35 min to complete. We developed a French adaptation of the BACS and this study tested its ease of administration and concurrent validity. Correlation analyses between the BACS (version A) and a standard battery were performed. A sample of 50 stable schizophrenic patients received the French Version A of the BACS in a first session, and in a second session a standard battery. All the patients completed each of the subtests of the French BACS . The mean duration of completion for the BACS French version was 36 min (S.D.=5.56). A correlation analysis between the BACS (version A) global score and the standard battery global score showed a significant result (r=0.81, p<0.0001). The correlation analysis between the BACS (version A) sub-scores and the standard battery sub-scores showed significant results for verbal memory, working memory, verbal fluency, attention and speed of information processing and executive functions (p<0.001) and for motor speed (p<0.05). The French Version of the BACS is easier to use in French schizophrenic patients compared to a standard battery (administration shorter and completion rate better) and its good psychometric properties suggest that the French Version of the BACS may be a useful tool for assessing cognition in schizophrenic patients with French as their primary language.

show abstract

Longitudinal neuropsychological findings from Stony Brook first episode study

Cited by 5 publications

References 0 publications

Neuropsychological functioning in adolescents with first episode psychosis: A two-year follow-up study

Neuropsychological functioning in adolescents with first episode psychosis: A two-year follow-up study

Cognitive insight and verbal memory in first episode of psychosis

Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients

Contact Info

Product

Resources

About